Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Atabecestat with CYP Substrates in Healthy Males
NCT02211079Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2014
- Primary completion
- Nov 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atabecestat in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at Day 9, Time to Reach Maximum Concentration at Day 9 and 6 more. Started Sep 2014; status: completed.
02
Drugs
atabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02211079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211079.